WO2014172448A3 - Anticorps diriges contre le recepteur d'activine de type ii (actrii) - Google Patents

Anticorps diriges contre le recepteur d'activine de type ii (actrii) Download PDF

Info

Publication number
WO2014172448A3
WO2014172448A3 PCT/US2014/034344 US2014034344W WO2014172448A3 WO 2014172448 A3 WO2014172448 A3 WO 2014172448A3 US 2014034344 W US2014034344 W US 2014034344W WO 2014172448 A3 WO2014172448 A3 WO 2014172448A3
Authority
WO
WIPO (PCT)
Prior art keywords
actrii
receptor type
activin receptor
chain polypeptide
directed against
Prior art date
Application number
PCT/US2014/034344
Other languages
English (en)
Other versions
WO2014172448A2 (fr
Inventor
Petra Verdino
Peter Bowers
David King
Original Assignee
Anaptysbio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio, Inc. filed Critical Anaptysbio, Inc.
Publication of WO2014172448A2 publication Critical patent/WO2014172448A2/fr
Publication of WO2014172448A3 publication Critical patent/WO2014172448A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

L'invention concerne un polypeptide à chaîne lourde d'immunoglobuline isolé et un polypeptide à chaîne légère d'immunoglobuline isolé qui se lient à une protéine récepteur d'activine de type II (ActRII) (par exemple, l'un ou l'autre et les deux de ActRIIA et/ou ActRIIB). L'invention concerne un agent de liaison à ActRII qui comprend le polypeptide à chaîne lourde d'immunoglobuline et le polypeptide à chaîne légère d'immunoglobuline mentionnés ci-dessus. L'invention concerne également des vecteurs, des compositions et des procédés d'utilisation associés de l'agent de liaison à ActRII pour traiter une maladie à médiation par ActRII.
PCT/US2014/034344 2013-04-17 2014-04-16 Anticorps diriges contre le recepteur d'activine de type ii (actrii) WO2014172448A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812789P 2013-04-17 2013-04-17
US61/812,789 2013-04-17

Publications (2)

Publication Number Publication Date
WO2014172448A2 WO2014172448A2 (fr) 2014-10-23
WO2014172448A3 true WO2014172448A3 (fr) 2015-01-08

Family

ID=51731973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/034344 WO2014172448A2 (fr) 2013-04-17 2014-04-16 Anticorps diriges contre le recepteur d'activine de type ii (actrii)

Country Status (1)

Country Link
WO (1) WO2014172448A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1855694B1 (fr) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Composition antisens permettant de traiter une atrophie musculaire
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2017062835A2 (fr) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
CN109311998A (zh) * 2016-02-22 2019-02-05 阿塞勒隆制药公司 用于增加免疫活性的ActRII拮抗剂
US10307455B2 (en) * 2016-03-10 2019-06-04 Acceleron Pharma Inc. Activin type 2 receptor antibodies
CN114127087A (zh) * 2019-05-30 2022-03-01 艾科赛扬制药股份有限公司 Actrii结合蛋白及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087000A1 (en) * 2005-08-19 2007-04-19 Walsh Frank S Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
US20100272734A1 (en) * 2009-04-27 2010-10-28 Novartis Ag Compositions and methods for increasing muscle growth
US20110052582A1 (en) * 2009-08-28 2011-03-03 Roche Glycart Ag Humanized Anti-CDCP1 Antibodies
US20110064751A1 (en) * 2009-08-17 2011-03-17 Roche Glycart Ag Targeted immunoconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087000A1 (en) * 2005-08-19 2007-04-19 Walsh Frank S Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
US20100272734A1 (en) * 2009-04-27 2010-10-28 Novartis Ag Compositions and methods for increasing muscle growth
US20110064751A1 (en) * 2009-08-17 2011-03-17 Roche Glycart Ag Targeted immunoconjugates
US20110052582A1 (en) * 2009-08-28 2011-03-03 Roche Glycart Ag Humanized Anti-CDCP1 Antibodies

Also Published As

Publication number Publication date
WO2014172448A2 (fr) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2014172448A3 (fr) Anticorps diriges contre le recepteur d'activine de type ii (actrii)
WO2014179664A3 (fr) Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
WO2015106080A3 (fr) Anticorps dirigés contre l'interleukine-33 (il-33)
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
WO2014055897A3 (fr) Anticorps monoclonaux humains anti pd-l1 et procédés d'utilisation
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
WO2020039321A3 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
EA201891066A1 (ru) Антитела к ror1
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
WO2014165082A3 (fr) Anticorps et procédés de détection
WO2017004026A8 (fr) Anticorps anti-cd 123 et conjugués et dérivés correspondants
WO2015013389A3 (fr) Anticorps monoclonaux anti-galectine-1 (gal1) et leurs fragments pour neutraliser gal1
WO2014200898A3 (fr) Protéines se liant à l'antigène neutralisant le cmv
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
EA201892440A1 (ru) Антитела к tl1a и их применения
WO2015009740A3 (fr) Agents de liaison anti-mucine 1 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14785005

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14785005

Country of ref document: EP

Kind code of ref document: A2